Philogen Spa (STU:78Q) Debt-to-EBITDA : -0.50 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Philogen Spa Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Philogen Spa's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.00 Mil. Philogen Spa's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €11.10 Mil. Philogen Spa's annualized EBITDA for the quarter that ended in Dec. 2023 was €-24.42 Mil. Philogen Spa's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.50.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Philogen Spa's Debt-to-EBITDA or its related term are showing as below:

STU:78Q' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.16 Med: -3.6 Max: -0.91
Current: -6.07

During the past 4 years, the highest Debt-to-EBITDA Ratio of Philogen Spa was -0.91. The lowest was -10.16. And the median was -3.60.

STU:78Q's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs STU:78Q: -6.07

Philogen Spa Debt-to-EBITDA Historical Data

The historical data trend for Philogen Spa's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen Spa Debt-to-EBITDA Chart

Philogen Spa Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-1.14

-0.91

-10.16

-6.07

Philogen Spa Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			-1.05	1.23	-0.98	0.59	-0.50

Competitive Comparison of Philogen Spa's Debt-to-EBITDA

For the Biotechnology subindustry, Philogen Spa's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Philogen Spa's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Philogen Spa's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Philogen Spa's Debt-to-EBITDA falls into.

Philogen Spa Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Philogen Spa's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1	+	11.1)	/	-1.993
	=	-6.07

Philogen Spa's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1	+	11.1)	/	-24.418
	=	-0.50

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Philogen Spa (STU:78Q) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Philogen Spa Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Philogen Spa's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Philogen Spa (STU:78Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen Spa (STU:78Q) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

PHIL:Italy

Address

Piazza La Lizza No. 7, Siena, ITA, 53100

Website

https://www.philogen.com

Philogen Spa is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, it derives a majority of revenue from the USA.

Philogen Spa (STU:78Q) Headlines

No Headlines